164 related articles for article (PubMed ID: 25400666)
1. Eculizumab therapy leads to rapid resolution of thrombocytopenia in atypical hemolytic uremic syndrome.
Tsai HM; Kuo E
Adv Hematol; 2014; 2014():295323. PubMed ID: 25400666
[TBL] [Abstract][Full Text] [Related]
2. Atypical Hemolytic Uremic Syndrome: A Meta-Analysis of Case Reports Confirms the Prevalence of Genetic Mutations and the Shift of Treatment Regimens.
Krishnappa V; Gupta M; Elrifai M; Moftakhar B; Ensley MJ; Vachharajani TJ; Sethi SK; Raina R
Ther Apher Dial; 2018 Apr; 22(2):178-188. PubMed ID: 29250893
[TBL] [Abstract][Full Text] [Related]
3. Terminal Complement Inhibitor Eculizumab in Adult Patients With Atypical Hemolytic Uremic Syndrome: A Single-Arm, Open-Label Trial.
Fakhouri F; Hourmant M; Campistol JM; Cataland SR; Espinosa M; Gaber AO; Menne J; Minetti EE; Provôt F; Rondeau E; Ruggenenti P; Weekers LE; Ogawa M; Bedrosian CL; Legendre CM
Am J Kidney Dis; 2016 Jul; 68(1):84-93. PubMed ID: 27012908
[TBL] [Abstract][Full Text] [Related]
4. Insights from the use in clinical practice of eculizumab in adult patients with atypical hemolytic uremic syndrome affecting the native kidneys: an analysis of 19 cases.
Fakhouri F; Delmas Y; Provot F; Barbet C; Karras A; Makdassi R; Courivaud C; Rifard K; Servais A; Allard C; Besson V; Cousin M; Châtelet V; Goujon JM; Coindre JP; Laurent G; Loirat C; Frémeaux-Bacchi V
Am J Kidney Dis; 2014 Jan; 63(1):40-8. PubMed ID: 24021908
[TBL] [Abstract][Full Text] [Related]
5. Safety and effectiveness of eculizumab for pediatric patients with atypical hemolytic-uremic syndrome in Japan: interim analysis of post-marketing surveillance.
Ito S; Hidaka Y; Inoue N; Kaname S; Kato H; Matsumoto M; Miyakawa Y; Mizuno M; Okada H; Shimono A; Matsuda T; Maruyama S; Fujimura Y; Nangaku M; Kagami S
Clin Exp Nephrol; 2019 Jan; 23(1):112-121. PubMed ID: 30039480
[TBL] [Abstract][Full Text] [Related]
6. Safety and effectiveness of eculizumab for adult patients with atypical hemolytic-uremic syndrome in Japan: interim analysis of post-marketing surveillance.
Kato H; Miyakawa Y; Hidaka Y; Inoue N; Ito S; Kagami S; Kaname S; Matsumoto M; Mizuno M; Matsuda T; Shimono A; Maruyama S; Fujimura Y; Nangaku M; Okada H
Clin Exp Nephrol; 2019 Jan; 23(1):65-75. PubMed ID: 29959568
[TBL] [Abstract][Full Text] [Related]
7. Eculizumab in secondary atypical haemolytic uraemic syndrome.
Cavero T; Rabasco C; López A; Román E; Ávila A; Sevillano Á; Huerta A; Rojas-Rivera J; Fuentes C; Blasco M; Jarque A; García A; Mendizabal S; Gavela E; Macía M; Quintana LF; María Romera A; Borrego J; Arjona E; Espinosa M; Portolés J; Gracia-Iguacel C; González-Parra E; Aljama P; Morales E; Cao M; Rodríguez de Córdoba S; Praga M
Nephrol Dial Transplant; 2017 Mar; 32(3):466-474. PubMed ID: 28339660
[TBL] [Abstract][Full Text] [Related]
8. Effect of eculizumab and recombinant human soluble thrombomodulin combination therapy in a 7-year-old girl with atypical hemolytic uremic syndrome due to anti-factor H autoantibodies.
Udagawa T; Motoyoshi Y; Matsumura Y; Takei A; Ariji S; Ito E; Chiga M; Nagasawa M; Morio T; Mizutani S
CEN Case Rep; 2014 May; 3(1):110-117. PubMed ID: 28509254
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of eculizumab in childhood atypical hemolytic uremic syndrome in Japan.
Ito N; Hataya H; Saida K; Amano Y; Hidaka Y; Motoyoshi Y; Ohta T; Yoshida Y; Terano C; Iwasa T; Kubota W; Takada H; Hara T; Fujimura Y; Ito S
Clin Exp Nephrol; 2016 Apr; 20(2):265-72. PubMed ID: 26156042
[TBL] [Abstract][Full Text] [Related]
10. Terminal complement inhibitor eculizumab in atypical hemolytic-uremic syndrome.
Legendre CM; Licht C; Muus P; Greenbaum LA; Babu S; Bedrosian C; Bingham C; Cohen DJ; Delmas Y; Douglas K; Eitner F; Feldkamp T; Fouque D; Furman RR; Gaber O; Herthelius M; Hourmant M; Karpman D; Lebranchu Y; Mariat C; Menne J; Moulin B; Nürnberger J; Ogawa M; Remuzzi G; Richard T; Sberro-Soussan R; Severino B; Sheerin NS; Trivelli A; Zimmerhackl LB; Goodship T; Loirat C
N Engl J Med; 2013 Jun; 368(23):2169-81. PubMed ID: 23738544
[TBL] [Abstract][Full Text] [Related]
11. Successful eculizumab treatment of recurrent postpartum atypical hemolytic uremic syndrome after kidney transplantation.
Garlo K; Dressel D; Savic M; Vella J
Clin Nephrol Case Stud; 2015; 3():8-13. PubMed ID: 29043127
[TBL] [Abstract][Full Text] [Related]
12. Application of a scoring system in Japanese patients diagnosed with atypical hemolytic uremic syndrome to assess the relationship between the score and clinical responses to eculizumab.
Wada H; Teranishi H; Shimono A; Kato N; Maruyama S; Matsumoto M
Thromb J; 2023 Apr; 21(1):43. PubMed ID: 37072821
[TBL] [Abstract][Full Text] [Related]
13. Relapse of Atypical Hemolytic Uremic Syndrome During Pregnancy in a Patient on Eculizumab Maintenance Treatment: A Case Report.
Fontana F; Alfano G; Bardhushi E; Ligabue G; Giovanella S; Neri I; Cappelli G
Am J Case Rep; 2019 Oct; 20():1460-1465. PubMed ID: 31582717
[TBL] [Abstract][Full Text] [Related]
14. Eculizumab is a safe and effective treatment in pediatric patients with atypical hemolytic uremic syndrome.
Greenbaum LA; Fila M; Ardissino G; Al-Akash SI; Evans J; Henning P; Lieberman KV; Maringhini S; Pape L; Rees L; van de Kar NC; Vande Walle J; Ogawa M; Bedrosian CL; Licht C
Kidney Int; 2016 Mar; 89(3):701-11. PubMed ID: 26880462
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of eculizumab in adult patients with atypical hemolytic uremic syndrome: A single center experience from Turkey.
Gediz F; Payzin BK; Ecemis S; Güler N; Yilmaz AF; Topcugil F; Berdeli A
Transfus Apher Sci; 2016 Dec; 55(3):357-362. PubMed ID: 27742267
[TBL] [Abstract][Full Text] [Related]
16. Improved renal recovery in patients with atypical hemolytic uremic syndrome following rapid initiation of eculizumab treatment.
Walle JV; Delmas Y; Ardissino G; Wang J; Kincaid JF; Haller H
J Nephrol; 2017 Feb; 30(1):127-134. PubMed ID: 26995002
[TBL] [Abstract][Full Text] [Related]
17. Atypical hemolytic uremic syndrome: a new drug program and first Polish adult patient treated with eculizumab.
Ruszkowski J; Heleniak Z; Dębska-Ślizień A
Pol Merkur Lekarski; 2018 Sep; 45(267):119-121. PubMed ID: 30240381
[TBL] [Abstract][Full Text] [Related]
18. Success of eculizumab in the treatment of atypical hemolytic uremic syndrome.
Baskin E; Gulleroglu K; Kantar A; Bayrakci U; Ozkaya O
Pediatr Nephrol; 2015 May; 30(5):783-9. PubMed ID: 25384530
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of Eculizumab Therapy for Atypical Hemolytic Uremic Syndrome Recurrence and Antibody-Mediated Rejection Progress After Renal Transplantation With Preformed Donor-Specific Antibodies: Case Report.
Yamamoto T; Watarai Y; Futamura K; Okada M; Tsujita M; Hiramitsu T; Goto N; Narumi S; Takeda A; Kobayashi T
Transplant Proc; 2017; 49(1):159-162. PubMed ID: 28104125
[TBL] [Abstract][Full Text] [Related]
20. Treatment of Atypical Hemolytic-Uremic Syndrome in the Era of Eculizumab.
Ebrahem R; Kadhem S; Truong Q
Cureus; 2017 Mar; 9(3):e1111. PubMed ID: 28439485
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
